Enanta Pharmaceuticals Announces Data Presentations at AASLD’s The Liver Meeting® 2021

Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ: ENTA) announced two poster presentations for its novel pangenotypic hepatitis B virus (HBV) core inhibitor EDP-514 at The Liver Meeting® 2021 from November 12-15, 2021. The data highlight preliminary results from a 28-day Phase 1b study in patients with chronic HBV. The presentations focus on EDP-514's ability to significantly reduce HBV DNA and RNA in viremic patients. These findings could advance Enanta's efforts in developing effective treatments for chronic HBV infections.

Positive

• EDP-514 shows promising results in reducing HBV DNA and RNA, indicating potential efficacy against chronic HBV.
• Two presentations at a significant medical conference enhance visibility and credibility in the biotech sector.

Negative

• None.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the company will have two poster presentations showcasing clinical data for EDP-514, a novel pangenotypic class II hepatitis B virus (HBV) core inhibitor, at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), being held November 12 – November 15, 2021. EDP-514 is being developed for use in combination treatments for patients with chronic HBV (CHB).

The meeting platform with posters will open on November 8, 2021 at 8:00 a.m. Enanta will have two poster presentations:

Poster Title: “EDP-514, A Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Preliminary Results of a 28-Day Phase 1b Study in Nuc-Suppressed CHB Patients”
Publication Number: 822
Session Title: Hepatitis B: Therapeutics: New Agents
Presenter: Jordan J. Feld, MD, MPH, Toronto Centre for Liver Disease, University Health Network, Toronto, Canada

Poster Title: “EDP-514, A Potent Pangenotypic Class II Hepatitis B Virus Core Inhibitor, Demonstrates Significant HBV DNA and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic Hepatitis B Infected Patients”
Publication Number: 823
Session Title: Hepatitis B: Therapeutics: New Agents
Presenter: Man Fung Yuen, MBBS, MD, PhD, DSc, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong

Further information about The Liver Meeting® 2021, hosted by AASLD, can be found at: https://www.aasld.org/the-liver-meeting .

About Enanta

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and non-alcoholic steatohepatitis (NASH). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211001005120/en/

Investor Contact

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

What presentations is Enanta Pharmaceuticals showcasing at The Liver Meeting 2021?

Enanta Pharmaceuticals is showcasing two poster presentations on EDP-514, a core inhibitor for chronic hepatitis B virus.

When is The Liver Meeting 2021 taking place?

The Liver Meeting 2021 will be held from November 12 to November 15, 2021.

What is EDP-514 developed for?

EDP-514 is developed as a pangenotypic core inhibitor for use in combination treatments for patients with chronic hepatitis B.

What are the preliminary study results for EDP-514?

Preliminary results from a 28-day Phase 1b study suggest that EDP-514 significantly reduces HBV DNA and RNA levels in patients.